TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback